AU2019217821B2 - Co-crystal forms of a novobiocin analog and proline - Google Patents

Co-crystal forms of a novobiocin analog and proline Download PDF

Info

Publication number
AU2019217821B2
AU2019217821B2 AU2019217821A AU2019217821A AU2019217821B2 AU 2019217821 B2 AU2019217821 B2 AU 2019217821B2 AU 2019217821 A AU2019217821 A AU 2019217821A AU 2019217821 A AU2019217821 A AU 2019217821A AU 2019217821 B2 AU2019217821 B2 AU 2019217821B2
Authority
AU
Australia
Prior art keywords
crystal
proline
crystal according
ray powder
powder diffractogram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019217821A
Other languages
English (en)
Other versions
AU2019217821A1 (en
Inventor
Melanie J. Bevill
Xin Jiang
Christopher S. Seadeek
Jared P. Smit
John Allen Walling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reata Pharmaceuticals Inc
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of AU2019217821A1 publication Critical patent/AU2019217821A1/en
Application granted granted Critical
Publication of AU2019217821B2 publication Critical patent/AU2019217821B2/en
Priority to AU2022283638A priority Critical patent/AU2022283638B2/en
Priority to AU2024227646A priority patent/AU2024227646A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
AU2019217821A 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline Active AU2019217821B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022283638A AU2022283638B2 (en) 2018-02-07 2022-12-05 Co-crystal forms of a novobiocin analog and proline
AU2024227646A AU2024227646A1 (en) 2018-02-07 2024-10-25 Co-crystal forms of a novobiocin analog and proline

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
US62/627,570 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022283638A Division AU2022283638B2 (en) 2018-02-07 2022-12-05 Co-crystal forms of a novobiocin analog and proline

Publications (2)

Publication Number Publication Date
AU2019217821A1 AU2019217821A1 (en) 2020-09-24
AU2019217821B2 true AU2019217821B2 (en) 2022-09-08

Family

ID=65444361

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2019217821A Active AU2019217821B2 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline
AU2022283638A Active AU2022283638B2 (en) 2018-02-07 2022-12-05 Co-crystal forms of a novobiocin analog and proline
AU2024227646A Pending AU2024227646A1 (en) 2018-02-07 2024-10-25 Co-crystal forms of a novobiocin analog and proline

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022283638A Active AU2022283638B2 (en) 2018-02-07 2022-12-05 Co-crystal forms of a novobiocin analog and proline
AU2024227646A Pending AU2024227646A1 (en) 2018-02-07 2024-10-25 Co-crystal forms of a novobiocin analog and proline

Country Status (19)

Country Link
US (3) US10717755B2 (enExample)
EP (1) EP3749675B1 (enExample)
JP (3) JP2021512910A (enExample)
KR (2) KR20240155354A (enExample)
CN (2) CN112020506B (enExample)
AR (1) AR114245A1 (enExample)
AU (3) AU2019217821B2 (enExample)
BR (1) BR112020016205A2 (enExample)
CA (2) CA3226385A1 (enExample)
CL (2) CL2020002051A1 (enExample)
CO (1) CO2020009761A2 (enExample)
EA (1) EA202091885A1 (enExample)
IL (2) IL315865A (enExample)
MX (2) MX2020008326A (enExample)
MY (1) MY209803A (enExample)
PE (1) PE20211446A1 (enExample)
SG (1) SG11202007530XA (enExample)
TW (3) TWI868593B (enExample)
WO (1) WO2019156907A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512910A (ja) * 2018-02-07 2021-05-20 リアタ ファーマシューティカルズ インコーポレイテッド ノボビオシン類似体とプロリンとの共結晶形態
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422320B2 (en) * 2012-02-09 2016-08-23 University Of Kansas C-terminal HSP90 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011306391B2 (en) * 2010-09-23 2016-12-15 Nuformix Limited Aprepitant L-proline composition and cocrystal
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CN104159584A (zh) * 2011-11-25 2014-11-19 诺弗米克斯有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
US9556216B2 (en) * 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CN106536498A (zh) 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
PL3202772T3 (pl) 2014-09-30 2021-02-22 Jiangsu Hengrui Medicine Co. Ltd. Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2
JP2021512910A (ja) 2018-02-07 2021-05-20 リアタ ファーマシューティカルズ インコーポレイテッド ノボビオシン類似体とプロリンとの共結晶形態

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422320B2 (en) * 2012-02-09 2016-08-23 University Of Kansas C-terminal HSP90 inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Kusuma, B. R. et al.; J. Med. Chem., 55, 5797-5812 (2012). DOI: 10.1021/jm300544c. *
Liu, M. et al; Eur. J. Pharm. Biopharm., 107, 151-159 (2016). DOI: 10.1016/J.EJPB.2016.07.008. *
Roy, L. et al.; "Chapter 11. Co-crystal Solubility and Thermodynamic Stability", Pharmaceutical Salts and Co-crystals, p.247-279 (UK, RSC Publishing, 2011). DOI: 10.1039/9781849733502-0024. *
Shan, N. et al.; Drug Discov., 13, 440-446 (2008). DOI: 10.1016/J.DRUDIS.2008.03.004. *
Springuel, G. et al.; Cryst. Growth Des., 12, 3374-3378 (2012). DOI: 10.1021/cg300307z. *
Vishweshwar, P. et al.; J. Pharm. Sci., 95, 499-516 (2006). DOI: 10.1002/JPS.20578. *

Also Published As

Publication number Publication date
IL276583B1 (en) 2024-11-01
SG11202007530XA (en) 2020-09-29
KR20240155354A (ko) 2024-10-28
AU2019217821A1 (en) 2020-09-24
TWI868593B (zh) 2025-01-01
PE20211446A1 (es) 2021-08-05
CN112020506B (zh) 2024-10-11
TWI797249B (zh) 2023-04-01
EA202091885A1 (ru) 2021-01-15
US11401294B2 (en) 2022-08-02
CL2022003784A1 (es) 2023-06-09
MX2020008326A (es) 2020-09-28
CN118894894A (zh) 2024-11-05
AR114245A1 (es) 2020-08-12
JP2026012851A (ja) 2026-01-27
CO2020009761A2 (es) 2020-10-30
TW202510893A (zh) 2025-03-16
NZ767558A (en) 2024-11-29
MY209803A (en) 2025-08-05
US20190241599A1 (en) 2019-08-08
IL276583A (en) 2020-09-30
US20200347088A1 (en) 2020-11-05
MX2022012856A (es) 2022-11-30
TW201945381A (zh) 2019-12-01
AU2024227646A1 (en) 2024-11-14
CA3090646A1 (en) 2019-08-15
EP3749675B1 (en) 2025-12-31
CA3090646C (en) 2024-02-27
US20240043465A1 (en) 2024-02-08
AU2022283638A1 (en) 2023-02-02
CL2020002051A1 (es) 2021-02-19
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CA3226385A1 (en) 2019-08-15
EP3749675A1 (en) 2020-12-16
WO2019156907A1 (en) 2019-08-15
JP2024001167A (ja) 2024-01-09
AU2022283638B2 (en) 2024-07-25
IL315865A (en) 2024-11-01
US10717755B2 (en) 2020-07-21
TWI915111B (zh) 2026-02-11
BR112020016205A2 (pt) 2020-12-15
IL276583B2 (en) 2025-03-01
JP2021512910A (ja) 2021-05-20
CN112020506A (zh) 2020-12-01
KR102718111B1 (ko) 2024-10-17

Similar Documents

Publication Publication Date Title
AU2022283638B2 (en) Co-crystal forms of a novobiocin analog and proline
US20240083902A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
JP2024546844A (ja) ピラゾロ［３，４－ｄ］ピリミジン化合物の固体形態
AU2020213989B2 (en) Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
KR20250084188A (ko) (2s,5r)-5-(2-클로로페닐)-1-(2'-메톡시-[1,1'-비페닐]-4-카르보닐)피롤리딘-2-카르복실산의다형체 및 이의 제조 방법
US20220235063A1 (en) Morphic forms of marizomib and uses thereof
EA049105B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
EA043335B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
KR20240168375A (ko) 고순도 화합물의 제조 방법 및 정제 방법
WO2026024591A1 (en) Tryptamine prodrug solid forms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)